Latest information for immunisation providers in Tasmania.
2 November 2016
22 August 2016
31 March 2016
01 December 2015
Hepatitis B Vaccination for High Risk Groups in Tasmania (November 2015)
08 May 2015
22 January 2015
30 September 2014
Recall of Meningitec® (Meningococcal serogroup C vaccine)
On 29 September 2014, Emerge Health in consultation with the Australian Government Department of Health Therapeutic Goods Administration (TGA) voluntarily recalled all unexpired doses of Meningitec® vaccine, due to the potential for particulate contamination.
Emerge Health has advised that a review of batches manufactured since October 2012 found a small number of syringes had been contaminated with iron oxide (rust) and oxidised stainless steel, both of which originated from manufacturing equipment. The review was prompted by two European reports of particulate matter in the syringes.
At the time of this recall, neither TGA nor Emerge Health were aware of any product complaints from patients or healthcare providers that suggest vaccine doses supplied in Australia have been contaminated.
All batches supplied in Australia identify Pfizer as the sponsor of Meningitec®
Meningitec® is no longer used in the National Immunisation Program (NIP), apart from infrequent catch-up dosing of older children in some jurisdictions. Alternative products are available for this purpose.
Since July 2013, a combined Meningococcal serogroup C and Haemophilus influenza type b vaccine has replaced the use of Meningitec® at age 12 months.
Immunisation providers in Tasmania have been advised that if they hold any stocks of Meningitec® vaccine, to quarantine and not use it.
Immunisation providers are being contacted by Emerge Health to arrange collection of the recalled vaccine (both NIP-supplied Meningitec®, and any other purchased stock).
Questions about this recall can be directed to Emerge Health on 03 9077 4486, (business hours), fax 03 8672 0792 or email (email@example.com).
Further information about this recall can be found on the TGA website: http://www.tga.gov.au/safety/alerts-medicine-meningitec-meningococcal-140929.htm
21 August 2013
ATAGI clinical advice for immunisation providers on the use of Menitorix® in delivering catch-up vaccinations, July 2013
25 June 2013
Changes to the NIP for Priorix-Tetra® (MMRV) and Menitorix® (Hib/MenC)
11 October 2012
The Prevenar 13® Supplementary Dose Program has now finished
27 February 2013
Childhood Immunisation Schedule
Due to the increase of pertussis in the community it is still recommended that the first doses of vaccines (usually scheduled at two months) can be brought forward to six weeks. The timing of subsequent doses can be continued from four months of age as per the Immunisation Schedule for Children in Tasmania 2012.
18 August 2011
Ongoing HPV vaccination program
Gardasil® is now scheduled for girls aged 12 or 13 years in either grade 6 or 7 as part of a school-based vaccination program. General Practitioners may also offer Gardasil® to girls who miss out at school or for those who prefer to attend a General Practice. Gardasil® vaccine is funded for all girls aged 12-16 years who have not already received three doses. Providers can place orders for Gardasil® with CDPU as per the usual ordering process for funded vaccines.
Call the Public Health Hotline - Tasmania on 1800 671 738